(Q36187025)

12 August 2017

1 reference

title

Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up? (English)

1 reference

12 August 2017

Jennifer S Isaacs

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

569-589

1 reference

Reduced levels of hsp90 compromise steroid receptor action in vivo

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Isolation of Hsp90 mutants by screening for decreased steroid receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Heat-shock protein hsp90 governs the activity of pp60v-src kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

From the cradle to the grave: molecular chaperones that may choose between folding and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Hsp90: an emerging target for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Clinical applications of angiogenic growth factors and their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Oxidative stress, redox, and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

A conserved family of prolyl-4-hydroxylases that modify HIF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

HIF activation by pH-dependent nucleolar sequestration of VHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Molecular basis of the VHL hereditary cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

JunD reduces tumor angiogenesis by protecting cells from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Requirement for generation of H2O2 for platelet-derived growth factor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Sustained production of H(2)O(2) activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Unusual expression and localization of heat-shock proteins in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Effect of geldanamycin on androgen receptor function and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Role of eNOS in neovascularization: NO for endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Phosphorylation analysis of 90 kDa heat shock protein within the cytosolic arylhydrocarbon receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Murine protein kinase CK2: gene and oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Bortezomib as a potential treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

DNA methylation in haematological malignancies: the role of decitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Chk1 and Chk2 kinases in checkpoint control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Hsp90 activation and cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Imaging angiogenesis: applications and potential for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Molecular imaging of antiangiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

21 January 2018

Putting the rap on Akt.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

21 January 2018

Heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Nanoparticle and targeted systems for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

Systems biology and new technologies enable predictive and preventative medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.569

10.1517/13543784.14.6.569

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference